Dr Reddy's

Six prominent pharmaceutical companies, including Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have signed memorandums of understanding (MoUs) with the Telangana government to set up facilities in the Pharma City near here, the government announced on Friday. The companies have committed to invest over Rs 5,260 crore, which is expected to create 12,490 job opportunities in the pharma sector, according to an official release. Representatives from the companies met with Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Secretariat to finalise the agreements. "The pharma company managements signed MoUs to establish the industries. The six companies expressed their interest to invest more than Rs 5260 crore. The investments will provide 12,490 job opportunities in the pharma sector. The government will allocate land for the establishment of the new pharma manufacturing units in the recognised pharma city, the release said. According to the MoUs

Dr Reddy's Laboratories and Sun Pharma are recalling products in the US due to manufacturing issues, as per the latest Enforcement Report by the US Food and Drug Administration (USFDA). According to the report, Dr Reddy's Laboratories is recalling drugs to treat insomnia and gout in the American market. New Jersey-based Dr Reddy's Laboratories, Inc., a unit of Hyderabad-based drug major, is recalling 13,752 bottles of Eszopiclone tablets, the USFDA stated. The affected lot has been produced at Dr Reddy's Bachupally plant in Telangana. As per the USFDA, the drug firm is recalling the affected lot due to "Failed Impurities/Degradation Specifications". The company issued the Class III nationwide recall on June 4 this year. As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". Dr Reddy's Laboratories, Inc. is also recalling 20,520 units of Allopurinol tablets in the

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Sun Pharma and Dr Reddy's Laboratories are recalling products in the American market due to manufacturing issues, the US Food and Drug Administration (USFDA) has said. In its latest Enforcement Report, the US health regulator stated that a US-based unit of Sun Pharma is recalling 35,069 bottles of medication used to treat high pressure inside the eye due to glaucoma or other eye diseases. New Jersey-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Xelpros (latanoprost ophthalmic emulsion) due to "out of specification for particulate matter test". The company initiated the voluntary Class III recall in the US on April 22 this year, the USFDA stated. In a separate filing, the USFDA stated that a US-based arm of Dr Reddy's Laboratories is recalling 1,176 bottles of an immunosuppressant medication. Dr Reddy's Laboratories Inc is recalling the affected lot of Sirolimus Tablets due to "Failed Impurities/Degradation Specifications", the USFDA said. The company ...

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Under the agreement, Dr Reddy's will market Vericiguat under the brand name Gantra

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

DRL said that it has acquired the entire MenoLabs supplements portfolio, which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause

In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India

Consolidated quarterly revenue rose 9% to 69.03 billion rupees led by a 9% growth in the key global generics segment

As per IIFL Securities, Cipla with a dominating market share of 7% and 23% in acute therapies like respiratory and anti-infectives, respectively, would strengthen Torrent's position in these

Amazon Web Services (AWS) on Monday announced that Dr. Reddy's Laboratories has selected it as preferred cloud provider to help provide access to affordable and innovative medicines. As part of the collaboration, the company has migrated its SAP platform entirely onto AWS. "By centralising the platform on the world's leading cloud, Dr. Reddy's will accelerate the development of new healthcare applications, grow its digital platform to help the organisation serve more than 1.5 billion patients by 2030 around the world, and enable healthcare providers to better track the progress of patients," according to a statement. Since 2019, Dr. Reddy's has been progressively creating and migrating digital applications to AWS to automate the company's IT infrastructure. "Leveraging AWS, Dr. Reddy's has made healthcare more accessible by launching new applications faster, to provide better service to its customers," the statement said. With AWS, Dr. Reddy's aims to reduce application developmen

Stocks to watch on July 10, 2023: BHEL, Delta Corp, Granules and India Cements are the four stocks in F&O ban period on Monday.

Exploring strategic collaborations in the country, says pharma firm

Among individual stocks, the technical & derivative analyst from HDFC Securities recommends to Buy Mahanagar Gas and Dr.Reddy's Labs.

In January Eris had bought some derma brands from Glenmark Pharma as well

As per the technical analyst, the Budget session high of 17,973 and low of 17,353 have become crucial levels to watch out for any directional move in the Nifty index

Stocks to Watch: Adani Enterprises FPO and Earthstahl & Alloys IPO opens for subscription on Friday. Shares of Adani Group companies also likely to be in focus amid the Hindenburg controversy.

Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv